Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

Summary

This phase II randomized trial studies how well bupropion hydrochloride works in improving sexual desire in women with breast or gynecological cancer. Bupropion hydrochloride may work by boosting sexual desire, energy, or motivation without causing intolerable or undesirable side effects.

Timeline

Start

2017-05-31

Primary completion

2021-02-22

Completion

2021-02-22

Outcome

Missed primary endpoint

registry analysis (superiority test); Bupropion 150 mg vs Placebo; p = 0.46; t-test, 1 sided NCT03180294 ↗

registry analysis (superiority test); Bupropion 300 mg vs Placebo; p = 0.54; t-test, 1 sided NCT03180294 ↗

paper Bupropion was not more effective than placebo in improving the desire subscale of the FSFI. PMID 34882500 ↗

Publications

• Barton DL, Pugh SL, Ganz PA, Plaxe SC, Koontz BF, Carter J, Greyz-Yusupov N, Page SJ, Rowland KM Jr, Balcueva EP, Nabeel S, Basil JB, Hill ML, Muller CY, Bell MC, Deshmukh S, Kachnic LA. Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004. J Clin Oncol. 2022 Feb 1;40(4):324-334. doi: 10.1200/JCO.21.01473. Epub 2021 Dec 9.

Drugs

Indications